Emily S Wong1, Claire W Y Chow, W K Luk, Kitty S C Fung, Kenneth K W Li. 1. *Hong Kong Eye Hospital, Hong Kong SAR, China; †Department of Ophthalmology and Visual Science, The Chinese University of Hong Kong, China; ‡Department of Ophthalmology, United Christian Hospital, Hong Kong SAR, China; Departments of §Ophthalmology; and ¶Pathology, Tseung Kwan O Hospital, Hong Kong SAR, China; ‖Department of Pathology, United Christian Hospital, Hong Kong SAR, China; and **Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Abstract
PURPOSE: To characterize epidemiological data on methicillin-resistant Staphylococcus aureus (MRSA) ocular infections over a 10-year period in Hong Kong; to compare the characteristics between hospital-associated methicillin-resistant Staphylococcus aureus (h-MRSA) and community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) ocular infections; and to review the treatment regimen and outcome of identified cases. METHODS: A retrospective case review of ocular samples testing positive for MRSA at a tertiary eye center from July 2005 to June 2015 was performed. RESULTS: Ninety nonduplicative samples from 75 patients with ocular MRSA infection were included during the study period. The average annual rate of ocular MRSA infection among all ocular S. aureus infections was 12.9%. Ten patients had CA-MRSA (13.3%). The most common clinical manifestation was preseptal cellulitis in the CA-MRSA group and blepharoconjunctivitis in the h-MRSA group. Vision-threatening conditions occurred only in the h-MRSA group. Besides vancomycin, other antibiotics to which both MRSA groups were highly sensitive included chloramphenicol, fusidic acid, cotrimoxazole, and gentamicin. Significantly more CA-MRSA was sensitive to levofloxacin and clindamycin (P < 0.01). The h-MRSA group required a significantly longer duration of treatment to eradicate infection (mean 79 vs. 28 days, P < 0.01). CONCLUSIONS: CA-MRSA presents as a genetically different organism with distinctive clinical presentation and antibiotic sensitivity from its h-MRSA counterpart. Despite increasing resistance patterns, we demonstrate that MRSA ocular infections can be effectively treated without the use of vancomycin, limiting its use to refractory or vision-threatening conditions.
PURPOSE: To characterize epidemiological data on methicillin-resistant Staphylococcus aureus (MRSA) ocular infections over a 10-year period in Hong Kong; to compare the characteristics between hospital-associated methicillin-resistant Staphylococcus aureus (h-MRSA) and community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) ocular infections; and to review the treatment regimen and outcome of identified cases. METHODS: A retrospective case review of ocular samples testing positive for MRSA at a tertiary eye center from July 2005 to June 2015 was performed. RESULTS: Ninety nonduplicative samples from 75 patients with ocular MRSA infection were included during the study period. The average annual rate of ocular MRSA infection among all ocular S. aureus infections was 12.9%. Ten patients had CA-MRSA (13.3%). The most common clinical manifestation was preseptal cellulitis in the CA-MRSA group and blepharoconjunctivitis in the h-MRSA group. Vision-threatening conditions occurred only in the h-MRSA group. Besides vancomycin, other antibiotics to which both MRSA groups were highly sensitive included chloramphenicol, fusidic acid, cotrimoxazole, and gentamicin. Significantly more CA-MRSA was sensitive to levofloxacin and clindamycin (P < 0.01). The h-MRSA group required a significantly longer duration of treatment to eradicate infection (mean 79 vs. 28 days, P < 0.01). CONCLUSIONS: CA-MRSA presents as a genetically different organism with distinctive clinical presentation and antibiotic sensitivity from its h-MRSA counterpart. Despite increasing resistance patterns, we demonstrate that MRSA ocular infections can be effectively treated without the use of vancomycin, limiting its use to refractory or vision-threatening conditions.
Authors: Jeffrey C Peterson; Heather Durkee; Darlene Miller; Jorge Maestre-Mesa; Alejandro Arboleda; Mariela C Aguilar; Nidhi Relhan; Harry W Flynn; Guillermo Amescua; Jean-Marie Parel; Eduardo Alfonso Journal: Infect Drug Resist Date: 2019-04-11 Impact factor: 4.003
Authors: Muhammad Kashif Salman; Muhammad Sohail Ashraf; Sumaira Iftikhar; Mirza Ahmad Raza Baig Journal: Pak J Med Sci Date: 2018 Sep-Oct Impact factor: 1.088